Vertex Pharmaceuticals Incorporated

DCF models suggest VRTX is trading approximately 41.8% below its intrinsic value of ~$801.77 per share, and its P/E of 27.3x compares favorably to the peer average of 42x. Institutional investors like Rockefeller Capital Management have significantly increased their stakes, signaling strong professional confidence in the company's long-term value.

Following a strong year-to-date rally, VRTX trades at a trailing P/E of ~31.4x and a PEG ratio of 2.01, exceeding historical medians and suggesting aggressive future growth is already priced in. Robert W. Baird reiterates an 'Underperform' rating with a $350 price target, implying steep downside from current levels.

Analysts who upgraded VRTX cite revenue diversification driven by the non-opioid pain drug Journavx and the gene-editing therapy Casgevy as highly lucrative growth avenues. Positive clinical data for suzetrigine further strengthened investor confidence, and the acquisition of Crinetics adds an approved rare-disease therapy and late-stage pipeline assets.

More conservative analysts, including Canaccord Genuity maintaining a 'Hold' rating with a target near $436, argue that current pricing already reflects anticipated pipeline contributions. They project lower profit margins and earnings of only ~$4.5 billion by the late 2020s, questioning whether new franchises can meaningfully offset CF portfolio concentration risk.

Optimistic analysts project 15.29% annual revenue growth, with earnings potentially reaching ~$8.8 billion by 2029 supported by the kidney franchise, gene-editing portfolio, and broader pipeline. HC Wainwright lifted its price target to $641 and maintains a 'Buy' rating, reflecting confidence in mid-teen revenue growth and expanding profit margins.

Conservative analysts forecast earnings of only ~$4.5 billion by the late 2020s under lower growth and margin assumptions. Weiss Ratings downgraded VRTX from 'Buy' to 'Hold', and the wide analyst price target dispersion of 12.14% — ranging from $330 to $641 — reflects deep uncertainty about the sustainability of Vertex's growth trajectory.